arrow
S

Sreyashi Basu

the university of texas
H指数:38
被引数:9,493

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial

纳武利尤单抗联合伊匹木单抗治疗化疗难治性转移性去势抵抗性前列腺癌:来自CheckMate 650试验2期随机部分的结果

2026-05-080
OAAI
Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma

双吞噬作用-检查点阻断在胶质母细胞瘤小鼠模型中恢复免疫监视

2026-03-090
OAAI
Integrative spatial multi-omics reveal niche-specific inflammatory signaling and differentiation hierarchies in AML

整合空间多组学揭示AML中微环境特异性的炎症信号和分化等级。

2025-11-290
OAAI
MULTI-OMIC AND SINGLE CELL ASSESSMENT OF SERIAL BIOPSIES REVEALS RESPONSES TO CAN-3110 ONCOLYTIC IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA THAT ARE NOT EVIDENT BY ROUTINE CLINICAL ANALYSES

多组学和单细胞评估连续活检揭示了CAN-3110溶瘤免疫疗法在复发性胶质母细胞瘤中的反应,这些反应在常规临床分析中并不明显

2025-11-010
OAAI
Investigative needle core biopsies support multimodal deep-data generation in glioblastoma

研究性针芯活检支持胶质母细胞瘤的多模式深度数据生成

2025-11-010
PRE
MESENCHYMAL STEM CELLS AND PERIVASCULAR STROMA ARE ASSOCIATED WITH MICROVASCULAR PROLIFERATION, IMMUNOSUPPRESSION, AND POOR OUTCOME IN GLIOMA

间充质干细胞和血管周基质与胶质瘤中的微血管增生、免疫抑制和不良预后相关

2025-11-010
OAAI
IMMUNE PROFILING OF GBM TUMOR TISSUES COLLECTED LONGITUDINALLY FROM PATIENTS TREATED WITH AN ONCOLYTIC VIRUS

纵向收集经溶瘤病毒治疗的患者的GBM肿瘤组织进行免疫分析

2025-11-010
OAAI
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses

串行多组学揭示了常规临床分析中未能显现的抗胶质母细胞瘤反应

2025-10-080
PRE
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy

癌症诱导的神经损伤促进抗PD-1疗法的耐药性

Nature
IF48.5
2025-08-200
OA
Multimodal spatial proteomic profiling in acute myeloid leukemia

急性髓系白血病中的多模态空间蛋白质组学分析

2025-05-200
OA
Investigative needle core biopsies support multimodal deep-data generation in glioblastoma

研究性针吸活检支持胶质母细胞瘤的多模式深度数据生成

2025-04-280
OA
Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade

髓样特异性KDM6B抑制使胶质母细胞瘤对PD1阻断敏感

2023-08-3110
OA
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

nivolumab联合依鲁替尼治疗CLL弥漫性大b细胞里氏转化患者的2期研究

2023-05-1039
OAAI
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
2023-03-228
OAAI
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

新辅助化疗联合nivolumab加或不加ipilimumab治疗可手术非小细胞肺癌: 2期平台NEOSTAR试验

2023-03-1694
OAAI